Latest / Morning Medical with Dr. Chow / Landmark Tobacco Settlement in Canada and FDA Greenlights Generic GLP-1 for Weight Loss

Transcript

Landmark Tobacco Settlement in Canada and FDA Greenlights Generic GLP-1 for Weight Loss · Morning Medical with Dr. Chow

• 0:00
  Welcome back to Morning Medical with Dr.
• 0:02
  Chow, your daily dose of the latest medical and health news from around the world, brought to
• 0:07
  you by artificial intelligence.
• 0:10
  I'm your host, Dr.
• 0:12
  Chi-Ming Chow.
• 0:15
  Today, we're diving into a landmark settlement involving major tobacco companies and its
• 0:21
  potential impact on public health in Canada.
• 0:27
  In a historic development, billions of dollars are set to flow into the coffers of Canadian
• 0:32
  provinces and territories starting this Friday, thanks to a monumental thirty-two point five
• 0:38
  billion dollar settlement with major tobacco companies.
• 0:42
  This settlement, sanctioned by an Ontario judge, marks a significant moment in the
• 0:46
  long-standing battle against tobacco-related health costs.
• 0:50
  The agreement involves three major tobacco companies: JTI-Macdonald Corporation, Rothmans,
• 0:57
  Benson & Hedges, and Imperial Tobacco Canada Limited.
• 1:02
  These companies have agreed to pay out billions in compensation to provinces, territories, and
• 1:08
  former smokers.
• 1:10
  This comes after years of mediation and legal battles, including two major class-action
• 1:15
  lawsuits in Quebec.
• 1:17
  Ontario and Quebec are leading the pack, each receiving over a billion dollars in initial
• 1:23
  payments, with other provinces also set to receive substantial amounts.
• 1:28
  The settlement will see about twenty-four billion dollars distributed to provinces and
• 1:33
  territories over the next two decades.
• 1:36
  Additionally, plaintiffs in the Quebec lawsuits will receive more than four billion dollars,
• 1:41
  with a claim period opening for them this Friday.
• 1:44
  Despite this financial windfall, anti-smoking advocates are urging provinces to utilize these
• 1:50
  funds to bolster public health programs focused on reducing tobacco use.
• 1:56
  Les Hagen from the Association for Action on Smoking and Health highlights that the
• 2:01
  settlement lacks any remedial actions.
• 2:04
  This means tobacco can still be sold and marketed without further restrictions, which is
• 2:10
  a significant concern given that approximately four million Canadians still smoke, leading to
• 2:16
  about forty-six thousand tobacco-related deaths annually.
• 2:20
  Flory Doucas, spokeswoman for the Coalition québécoise pour le contrôle du tabac, expressed
• 2:26
  her concerns that without new measures limiting the tobacco industry's ability to attract new
• 2:32
  customers and without adequate funding for tobacco-reduction initiatives, the settlement
• 2:37
  might merely serve as a financial boon rather than a public health breakthrough.
• 2:43
  Doucas warns that without these measures, future generations may still fall prey to the
• 2:48
  tobacco industry's predatory practices.
• 2:52
  The settlement also includes a provision for more than one billion dollars to be allocated
• 2:57
  to a foundation dedicated to fighting tobacco-related diseases.
• 3:02
  This includes one hundred thirty-one million dollars taken from the Quebec plaintiffs'
• 3:06
  allocation.
• 3:08
  While this is a step in the right direction, public health advocates continue to call for
• 3:13
  more comprehensive tobacco-reduction strategies to be funded by these settlement dollars.
• 3:18
  On the legal front, Ontario Superior Court Chief Justice Geoffrey Morawetz approved a
• 3:25
  staggering nine hundred nine million dollars in legal fees for the class-action lawyers who
• 3:30
  have been battling tobacco companies for decades.
• 3:34
  Nearly nine hundred million of this amount is designated for Quebec counsel, whose clients
• 3:39
  are set to receive nearly four billion dollars.
• 3:43
  Chief Justice Morawetz acknowledged the unprecedented nature of this fee but found it
• 3:48
  reasonable given the complexity and significance of the case.
• 3:53
  This settlement represents a pan-Canadian resolution of all outstanding tobacco
• 3:57
  litigation in the country, with claims against the companies initially totaling over one
• 4:02
  trillion dollars.
• 4:03
  As the funds begin to flow, the focus remains on how these resources will be used to tackle
• 4:08
  the ongoing public health challenge posed by tobacco.
• 4:13
  In other news, the Food and Drug Administration has approved the first-ever generic version of
• 4:18
  a GLP-1 receptor agonist specifically for weight loss.
• 4:23
  This is a significant development announced by Teva Pharmaceuticals.
• 4:27
  The generic form of liraglutide, known as Saxenda, is now available for adults dealing
• 4:32
  with obesity or those who are overweight with at least one weight-related comorbidity.
• 4:38
  This medication is to be used in combination with diet and exercise.
• 4:43
  Additionally, it's been approved for adolescents aged twelve to seventeen who weigh
• 4:47
  over one hundred thirty-two point two pounds and are classified as obese.
• 4:53
  Liraglutide was initially approved in 2014 for chronic weight management in adults and
• 4:59
  expanded in 2020 to include teens.
• 5:01
  This approval comes amidst a surge in demand for GLP-1 drugs, which are increasingly popular
• 5:07
  in weight-loss treatments.
• 5:09
  However, cost and accessibility have been significant barriers, with brand-name versions
• 5:15
  of liraglutide previously appearing on the Food and Drug Administration's drug shortage list
• 5:20
  due to high demand.
• 5:22
  Teva Pharmaceuticals stated that the introduction of this generic version is aimed
• 5:26
  at addressing the growing demand for GLP-1 therapies in the United States market.
• 5:32
  While this is the first generic GLP-1 specifically for weight loss, other generics
• 5:37
  have been approved for managing type 2 diabetes, including liraglutide under the brand
• 5:42
  name Victoza and exenatide known as Byetta.
• 5:48
  In clinical trials spanning fifty-six weeks, liraglutide showed an average weight loss of
• 5:54
  twelve point three pounds in adults and nine point nine pounds in adolescents compared to a
• 6:01
  placebo.
• 6:02
  Although these results are modest when compared to newer GLP-1 agents like tirzepatide and
• 6:08
  semaglutide, which demonstrated more substantial weight loss, the availability of a
• 6:14
  generic option could make this treatment more accessible to those in need.
• 6:19
  It's important to note that the label for generic liraglutide includes a boxed warning
• 6:23
  for the risk of thyroid C-cell tumors.
• 6:26
  Patients with a personal or family history of medullary thyroid carcinoma or multiple
• 6:30
  endocrine neoplasia syndrome type 2 should avoid this medication.
• 6:35
  Other warnings include potential risks of acute pancreatitis, gallbladder disease,
• 6:42
  hypoglycemia, increased heart rate, acute kidney injury, severe gastrointestinal
• 6:48
  reactions, and hypersensitivity reactions.
• 6:51
  The drug is not recommended for patients under six years old, and its use during pregnancy
• 6:56
  should be carefully considered against potential risks to the fetus.
• 7:01
  Common side effects reported include nausea, diarrhea, constipation, vomiting,
• 7:07
  injection-site reactions, headaches, and dizziness among others.
• 7:11
  Although these side effects are generally manageable, it's crucial for patients and
• 7:15
  healthcare providers to weigh the benefits and risks when considering this medication for
• 7:20
  weight loss.
• 7:21
  With this new generic approval, the hope is to make effective weight management solutions more
• 7:27
  accessible to a broader population, particularly those who may have been deterred
• 7:32
  by the high costs of brand-name medications.
• 7:36
  As with any medication, it's essential to consult with healthcare professionals to
• 7:40
  determine the best approach for individual needs and circumstances.
• 7:45
  That's all for today's episode of Morning Medical with Dr.
• 7:48
  Chow.
• 7:49
  Thank you for tuning in as we explored the latest developments in the fight against
• 7:53
  tobacco-related health costs and breakthroughs in weight-loss treatments.
• 7:57
  Join us tomorrow for more updates on the medical and health news that matter.
• 8:01
  Until then, take care and stay healthy.